Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;28(3):245-252.
doi: 10.5114/wo.2024.144222. Epub 2024 Oct 15.

The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients - the final analysis of the Polish real-life survey PONDx

Michał Jarząb  1 , Maria Litwiniuk  2   3 , Paige Innis  4 , Aleksandra Łacko  5 , Gesine Enderle  6 , Bogumiła Czartoryska-Arłukowicz  7 , Małgorzata Talerczyk  8 , Joanna Streb  9   10 , Piotr Wysocki  9   10 , Grażyna Suchodolska  11 , Bartosz Szymanowski  12 , Renata Duchnowska  12
Affiliations

The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients - the final analysis of the Polish real-life survey PONDx

Michał Jarząb et al. Contemp Oncol (Pozn). 2024.

Abstract

Introduction: Breast cancer (BC) is among the most frequently diagnosed malignant tumours in females. The optimal treatment of early HR+, HER2-, and lymph node-negative (N0) BC remains challenging. Since individual assessment of recurrence risk and expected benefits from adjuvant chemotherapy (CT) based on clinicopathological features alone appear inadequate, gene expression profiling tests have been developed. This study aimed to evaluate the impact of Oncotype DX Breast Recurrence Score® (Oncotype DX Breast RS) test results on physicians' decisions concerning adjuvant CT in the Polish population.

Material and methods: The PONDx survey investigated the real-life use of Oncotype DX Breast RS in 204 pa- tients with HR+, HER2-, N0 BC in 8 clinical reference centres in Poland. Data on clinicopathological features and changes in treatment based on the Oncotype DX Breast RS test were collected.

Results: Chemotherapy plus endocrine therapy (ET) was initially recommended in 44.8% and ET alone in 55.2% of patients. After the introduction of recurrence score results, the recommendation for CT decreased significantly: relative reduction of 25.5% (95% CI: 11.7-52.3) and absolute reduction of 11.4% (95% CI: 1.9-21.0). Among patients initially recommended for CT, treatment was de-escalated in 62.2%; conversely, among patients initially recommended for ET alone, 29.7% were escalated to CT after testing. The relative reduction was especially pronounced in post-menopausal patients (29.6%) and in those with lobular BC (42.9%).

Conclusions: The Oncotype DX Breast RS result significantly influenced treatment decisions, with 44.3% of patients changing treatment, thus avoiding overtreatment or undertreatment. The Oncotype DX Breast RS test improves patient management and increases physician confidence in treatment recommendations.

Keywords: Oncotype DX Breast Recurrence Score®; adjuvant chemotherapy; breast cancer; real life study.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Overall reduction in chemotherapy administered based on the Oncotype DX Breast Recurrence Score® result
Fig. 2
Fig. 2
Reduction in chemotherapy administered based on the Oncotype DX Breast Recurrence Score® test in pre- and post-menopausal patients
Fig. 3
Fig. 3
Reduction in chemotherapy administered based on the Oncotype DX Breast Recurrence Score® test in patients with ductal and lobular breast cancer
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Partridge AH, Rumble RB, Carey LA, et al. . Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: Ame-rican Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014; 32: 3307-3329. - PMC - PubMed
    1. Wojciechowska U, Barańska K, Miklewska M, Didkowska JA. Cancer incidence and mortality in Poland in 2020. NOWOTWORY J Oncol 2023; 73: 129-145.
    1. Roth MY, Elmore JG, Yi-Frazier JP, Reisch LM, Oster NV, Miglioret-ti DL. Self-detection remains a key method of breast cancer detection for U.S. women. J Womens Health (Larchmt) 2011; 20: 1135-1139. - PMC - PubMed
    1. Barni S, Cognetti F, Petrelli F. Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Ita-lian PONDx study. Breast Cancer Res Treat 2022; 191: 477-480. - PubMed
    1. Syed YY. Oncotype DX Breast Recurrence Score(®): a review of its use in early-stage breast cancer. Mol Diagn Ther 2020; 24: 621-632. - PubMed